Losartan and HCTZ and Amlodipine Vs Atenolol and Amlodipine
Information source: Merck
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: MK0954, losartan potassium/Duration of Treatment: 18 weeks (Drug); Comparator: losartan, HCTZ, amlodipine, atenolol/Duration of Treatment: 18 weeks (Drug)
Phase: Phase 4
Status: Active, not recruiting
Sponsored by: Merck Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Merck
Summary
A study to evaluate the effects of combination losartan versus combination atenolol in
patients with ambulatory systolic hypertension.
Clinical Details
Official title: Antihypertensive Effects of a Fixed-Dose Combination of Losartan and Hydrochlorothiazide Plus Amlodipine Versus a Hydrochlorothiazide and Atenolol Combination Plus Amlodipine in Subjects With Ambulatory Systolic Hypertension.
Study design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: Mean daytime ambulatory systolic blood pressure
Secondary outcome: Ambulatory BPPulse pressure Trough sitting BP Percentage of patients who reach goal ambulatory systolic BP
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Males or females at least 18 years of age who have ambulatory systolic hypertension.
Locations and Contacts
Merck Frosst Canada Ltd., Kirkland, Quebec H9H3L1, Canada
Additional Information
Starting date: February 2003
Last updated: October 27, 2005
|
